Ascentage Pharma Reports Strong Phase II Results for Lisaftoclax in BTK-Refractory CLL/SLL

Ascentage Pharma Group International has announced the presentation of pivotal data from a China registrational Phase II study of Lisaftoclax (APG-2575) monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who were refractory to Bruton’s tyrosine kinase inhibitors (BTKis). The results, which were presented in an oral report at the 2025 American Society of Hematology (ASH) Annual Meeting, showed that Lisaftoclax achieved a 62.5% objective response rate in heavily pretreated, BTKi-refractory patients, nearly half of whom had complex karyotype. The study also reported a median progression-free survival of 23.89 months, with no cases of tumor lysis syndrome observed. The data supported the new drug application (NDA) approval of Lisaftoclax by China’s National Medical Products Administration in July 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-118963), on December 08, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here